AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Company: | AlloVir | ||
| |||
Headquarters Address: | 139 Main Street | ||
| Suite 500 | ||
| Cambridge, MA 02142 | ||
| |||
Main Telephone: | 617-433-2605 | ||
| |||
Website: | |||
| |||
Ticker/ISIN: | ALVR(NASDAQ)/US0198181036 | ||
| |||
Type of Organization: | Public | ||
| |||
Industry: | Biotechnology | ||
| |||
Key Executives: | CEO: David Hallal | ||
| CFO: Vikas Sinha | ||
| |||
Investor Relations | |||
Contact: | Medha Chadha | ||
Phone: | 917-765-2125 | ||
Email: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005944/en/
